English
|
Español
English
|
Español
Insurance
Marketing
Pharmaceuticals
Technology/Innovation
Regulatory
Community
Janssen
Press release submission
| Dec 29, 2021
Janssen Submits Biologics License Application to U.S. FDA Seeking Approval of Teclistamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Press release submission
| Dec 22, 2021
FDA Approves Two New Indications for XARELTO® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
Press release submission
| Aug 19, 2021
Janssen Presents Phase 1 Results for RYBREVANT™ (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations
Press release submission
| May 21, 2021
RYBREVANT™ (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Press release submission
| Jan 16, 2019
JANSSEN: Announces European Commission approval of ERLEADA®(apalutamide) for non-metastatic castration-resistant prostate cancer patients who are at high risk of developing metastatic disease
Press release submission
| Dec 6, 2018
JANSSEN: DARZALEX® (daratumumab) Combination Regimens Show Positive Results for Newly Diagnosed and Relapsed Patients with Multiple Myeloma
Trending
Patient Daily
| Sep 3, 2025
Top healthcare marketing experts to present at AOCOO-HNS 2025 virtual mid-year symposium, led by Greg Caesar of Medfluence Advisors
+
Pharmaceuticals
Patient Daily
| Sep 4, 2025
PhRMA CEO on 340B abuse: ‘Big hospitals are abusing the 340B program to markup medicine prices’
+
Pharmaceuticals
Patient Daily
| Sep 2, 2025
Fmr. Gov. Dean on 340B: ‘There's no actual requirement for hospitals to pass along the savings’
+
Pharmaceuticals
Patient Daily
| Aug 29, 2025
Deputy VP of Public Affairs of PhRMA on 340B: ‘Over 80% of all rural hospital beds were actually in urban hospitals’
